"Abiraterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
Descriptor ID |
D000069501
|
MeSH Number(s) |
D04.210.500.054.079.065
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Abiraterone Acetate".
Below are MeSH descriptors whose meaning is more specific than "Abiraterone Acetate".
This graph shows the total number of publications written about "Abiraterone Acetate" by people in this website by year, and whether "Abiraterone Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Abiraterone Acetate" by people in Profiles.
-
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. 2021 08 15; 127(16):2954-2965.
-
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20; 32(30):3436-48.